- 《HIV Therapy》
- 语言：外文
- ISSN：1758-4310
- 周期：双月刊
- 学科分类：
- 简介：Substantial advances in the development of antiretroviral drugs and clinical management are being ac...
更多...-
- 简介：Substantial advances in the development of antiretroviral drugs and clinical management are being achieved in the field of HIV and AIDS, although many research challenges remain. In recognition of an increased focus on contemporary clinical challenges and disease management issues, Future HIV Therapy (ISSN: 1746-9600) will simply be titled HIV Therapy (ISSN: 1758-4310) from January 2009. Research into HIV has now been ongoing for a quarter of a century, with the first official case of AIDS being reported in the USA in 1981. Since that time, and the discovery of the causative link with HIV by researchers first in France and then the USA, great strides have been made in understanding the replication cycle, pathogenesis and epidemiology of this virus. However, in spite of the resources, time, money and effort dedicated to AIDS research in that time, AIDS has been responsible for the deaths of more than 25 million people worldwide, of which at least a third have been in sub-Saharan Africa. There are now some 20 anti-HIV agents available, along with combination therapies, with many more in the development pipeline. In addition to developing more drugs in the established classes, current and future research will focus on new antiviral targets, such as entry, integrase and maturation inhibitors, to augment and possibly replace the available therapeutic armamentarium. A great deal of funding is also being focused on the development of a preventative HIV vaccine, with the Center for HIV/AIDS Vaccine Immunology being set up by the NIH in 2005, and the Bill & Melinda Gates Foundation donation of US$287 million over 5 years to 16 groups involved in vaccine research. This highlights the position of HIV/AIDS as a top public health priority. Therefore, the goal for the HIV research community continues to be to develop new treatments to target the virus and any resistant strains that might develop, and also to improve side effects, adherence and education, simplify drug regimens and reduce costs. In addition, the ultimate aim should be the complete eradication of HIV from an infected immune system. HIV Therapy (ISSN: 1758-4310) will keep researchers up-to-date with the significant advances that will take us toward these goals. Articles published in HIV Therapy include key areas such as: The molecular basis of HIV infection Virus–host interactions Optimal therapeutic approaches, including drug choice and treatment strategies Potential future viral targets Summaries evaluating newly approved anti-HIV agents Postmarketing research, including adverse events and drug safety, pharmacoeconomics and cost–benefit issues in HIV therapy Epidemiological studies and trends HIV drug resistance New and improved diagnostic methods Vaccine development, prevention measures and prophylaxis HIV Therapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this globally important area of research.
HIV Therapy is pleased to be one of the Future Science Group journals participating in the HINARI program. The HINARI program, set up by WHO together with major publishers, enables developing countries to gain access to one of the world's largest collections of biomedical and health literature. Over 3750 journal titles are now available to health institutions in 113 countries, benefiting many thousands of health workers and researchers, and in turn, contributing to improved world health. For further information visit the HINARI programme website.
隐藏-
- 来源数据库：
- 国家科技图书文献中心文献检索
- Future Science Group
- PHMC(ProQuest-Health & Medical Complete)
- ProQuest检索平台
